Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.
about
Leveraging the cortical cholinergic system to enhance attentionToward developmental models of psychiatric disorders in zebrafishScopolamine impairs auditory delayed matching-to-sample performance in monkeysEvaluation of animal models of neurobehavioral disorders.The reinstatement model and relapse prevention: a clinical perspective.Preclinical psychopharmacology of AIDS-associated dementia: lessons to be learned from the cognitive psychopharmacology of other dementias.Mild cognitive impairment: animal models.A pharmacological analysis of an associative learning task: 5-HT(1) to 5-HT(7) receptor subtypes function on a pavlovian/instrumental autoshaped memory.Effects of pregnanolone and flunitrazepam on the retention of response sequences in rats.nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms.Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.Cognitive correlates of single neuron activity in task-performing animals: application to ethanol research.Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.Aniracetam improves behavioural responses and facilitates signal transduction in the rat brain.Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease.Intermittent ethanol exposure increases long-lasting behavioral and neurochemical effects of MDMA in adolescent mice.
P2860
Q24598925-48887EE6-68CF-4A06-95FB-BB0CE37EC00DQ26830848-15672DA0-5846-47FC-A058-E2D12243AB19Q30488924-48BAF94F-CA3C-41E9-B5AE-8F839973F990Q30490127-0DFE4E2D-3FDB-4ED1-BEAB-297299EB4414Q34062912-7222DFF4-9AB5-44D8-8F6C-1E2B131822F8Q34098757-20B85EB3-AF60-486D-BCE2-F9829184DB47Q35236831-8AF6F0FD-E5B2-4997-812D-24651E3CF582Q35558964-1F542D8A-1DCE-4D26-91B7-9169D9C56283Q35818198-790B61D2-DCEB-47E8-8F9D-62C958FD0BFDQ37465460-E3C48DF3-3F5B-4D58-9588-DB3CDB84FB34Q41676772-99EAFFAA-1F9A-4085-9010-5BECC661EDF8Q41726496-5F3D7C13-DC89-4C96-AF0C-8B7A18660964Q44317349-20EB3F81-5594-44B4-9DC9-B7956E1A7F21Q46840300-7A8BA997-6947-41B9-B97D-8B6A5553A3B4Q48192489-AF184271-6FAD-44E4-8409-2BE42AF65CC5Q48298529-EC3799E8-5C54-4872-8DF3-DE12819F40B1Q50629599-F28A439F-26CB-4BAD-93A3-27E964C17D81
P2860
Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Behavioral screening for cogni ...... nate to valid testing: Part I.
@ast
Behavioral screening for cogni ...... nate to valid testing: Part I.
@en
type
label
Behavioral screening for cogni ...... nate to valid testing: Part I.
@ast
Behavioral screening for cogni ...... nate to valid testing: Part I.
@en
prefLabel
Behavioral screening for cogni ...... nate to valid testing: Part I.
@ast
Behavioral screening for cogni ...... nate to valid testing: Part I.
@en
P2093
P2860
P356
P1433
P1476
Behavioral screening for cogni ...... nate to valid testing: Part I.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF02245132
P577
1992-01-01T00:00:00Z